



BIOHEART

Media Contact: Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 772.285.8511
cmatton@bioheartinc.com

For Immediate Release

**BIOHEART TO PRESENT AT SELECTBIO CLINICAL
TRANSLATION OF STEM CELLS**

Sunrise, FL – April 2, 2014 – Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and commercialization of autologous cell therapies, announced that it will present at the **SELECTBIO 2nd Annual Clinical Translation of Stem Cells** on April 21st, 2014. The conference brings together basic scientists, clinician-scientists, as well as medical practitioners/surgeons focusing on studying, characterizing, and deploying various classes of stem cells for therapeutic utility.

Kristin Comella, Bioheart’s Chief Scientific Officer, will present a summary of data on the use of stem cells to treat a variety of indications. She will also provide a live demonstration in the “hands-on” clinical practicum. **SELECTBIO** has partnered with surgeons and a surgery center in the Palm Springs area to offer conference delegates the ability to observe adipose tissue extraction and processing *ex vivo* in real time.

This "hands-on" demonstration led by leading surgeons in the field is in full compliance with applicable laws and regulations and performed by board-certified surgeons. This conference therefore provides valuable learning and networking experiences for both basic researchers and clinicians alike seeking the most up-to-date information, protocols, and products in this emerging field.

About Bioheart, Inc.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013.